Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies
Serkan Özakbaş, Cavid Baba, Yavuz Doğan, Sümeyye Çevik, Sinem Özçelik, Ergi Kaya
Topics & Concepts
MedicineMultiple sclerosisTiterImmune systemAntibodyImmunologyDiseaseAntibody responseCoronavirus disease 2019 (COVID-19)PopulationAntibody titerSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Internal medicineInfectious disease (medical specialty)Environmental healthMultiple Sclerosis Research StudiesSARS-CoV-2 and COVID-19 ResearchPeripheral Neuropathies and Disorders